Predict your next investment

Complix company logo
HEALTHCARE | Drug Development
complix.com

See what CB Insights has to offer

Executives

1

Board of Directors

3

Complix Board of Directors

3 Board of directors

Complix has 3 board of directors, including Christophe Van Vaeck.

Name

Firm

Work History

Other Seats

Christophe Van Vaeck

Almaviva Sante, Almaviva Sante, Biotalys, Multiplicom, and Spineart

Hans Schikan

Hans Schikan is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) in June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 mln. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Hans is currently Chairman of the Board of Complix (Belgium), Board Member of Vicore Pharma (publ, Sweden), VectivBio (Switzerland) and Pharvaris (Netherlands). He is also Member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands). Previously he served on the boards of Wilson Therapeutics (acquired by Alexion), Therachon (acquired by Pfizer), Sobi, Asceneuron and Hansa Biopharma. He has a PharmD from Utrecht University

Asceneuron, InteRNA Technologies, Pharvaris, Therachon, and VectivBio

Johan Cardoen

Aphea.Bio, Biotalys, Confo Therapeutics, and Meiogenix

Name

Christophe Van Vaeck

Hans Schikan

Johan Cardoen

Firm

Work History

Hans Schikan is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) in June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 mln. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Hans is currently Chairman of the Board of Complix (Belgium), Board Member of Vicore Pharma (publ, Sweden), VectivBio (Switzerland) and Pharvaris (Netherlands). He is also Member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands). Previously he served on the boards of Wilson Therapeutics (acquired by Alexion), Therachon (acquired by Pfizer), Sobi, Asceneuron and Hansa Biopharma. He has a PharmD from Utrecht University

Other Seats

Almaviva Sante, Almaviva Sante, Biotalys, Multiplicom, and Spineart

Asceneuron, InteRNA Technologies, Pharvaris, Therachon, and VectivBio

Aphea.Bio, Biotalys, Confo Therapeutics, and Meiogenix

Complix Management Team

1 Team Member

Complix has 1 executive. Complix's current Chief Executive Officer is Mark Vaeck.

Name

Work History

Title

Status

Mark Vaeck

Chief Executive Officer

Current

Name

Mark Vaeck

Work History

Title

Chief Executive Officer

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.